Loading
companiesCompany
Tempus AI
Genomic testing plus one of the largest multimodal clinical datasets, used for AI models and trial matching.
Overview
Tempus AI, based in Chicago and listed as TEM, pairs genomic testing with one of the largest multimodal clinical datasets, used to build AI models and match patients to trials. It sells xT, a 648-gene panel with an FDA-approved CDx version, xR for RNA, xF and xM for liquid biopsy and MRD, the TIME trial matching service and algorithms such as Tempus ECG-AF, and it owns Ambry Genetics for germline testing, with Personalis and Deep 6 AI also linked. OnCo links it to comprehensive genomic profiling, AI trial matching, oncology real-world data platforms and multimodal models, and to bottlenecks on AI that is built but not validated, data silos and patient navigation, with ideas on a shared multimodal foundation model attached. Whether its data advantage produces validated clinical tools rather than only revenue is the open question. Tempus xT CDx has its own page.
Headquarters
Chicago, IL, US
Scorecard
All companies#308of 1244 companies, score 13
- approved products +6
- targets +4
- modalities +2
- regions +1
1 approved, 0 in phase 3, 0 earlier, 2 targets, 0 registry studies. Formula on the scorecards page.
Deals
Deal map| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2026-07 | Personalis (Tempus) to Tempus AI NeXT Personal tumour-informed MRD test | Acquisition | not disclosed | about $1.5bn in stock ($16.25 per share) | source |
Catalysts
What is due next- Q4 2026expectedTempus completes the acquisition of Personalis
All-stock deal at $16.25 per share announced July 2026; the companies guided to a close in late 2026 or early 2027. Source
Type
AI & software · TEM
Stage
Public
Website
ApprovedTissue NGS companion diagnostic test (648 genes, tumour-normal)
Tempus xT CDx · xT CDx
Tempus's tumour-and-normal gene panel, FDA-approved in 2023 as a companion test for EGFR antibodies in bowel cancer.
Similar pages
- CompanyFoundation Medicine (Roche)
Shares A global federated real-world evidence network at regulatory grade, Emulate combination trials from real-world data to triage which ones to run, Label every targetable mutation as truncal or branch on the report, A single calibrated tumour mutational burden across all sequencing panels.
- CompanyOwkin
Shares A pre-competitive consortium to train a shared multimodal cancer foundation model, Digital twins and virtual control arms, Patient-level multimodal foundation models for treatment selection, Pathology & radiology foundation models.
- CompanyGuardant Health
Shares Label every targetable mutation as truncal or branch on the report, Every tumour sequencing report lists open, nearby, matched trials pulled live, Every tumour genomic report machine-readable and deposited nationally, Weak real-world evidence and registries.
- RoadmapAI in the oncology clinic: from narrow cleared tools to multimodal decision support
Shares Tempus multimodal models, Patient-level multimodal foundation models for treatment selection, AI trial matching & clinical decision support, Pathology & radiology foundation models.
- IdeaFederated training of pathology and radiology models across hospitals
Shares A pre-competitive consortium to train a shared multimodal cancer foundation model, Pathology & radiology foundation models, AI that is built but not validated or deployed, Data silos.
- IdeaPool every immunotherapy trial's biomarker data into one commons
Shares Patient-level multimodal foundation models for treatment selection, Pathology & radiology foundation models, AI that is built but not validated or deployed, No one can predict who responds to immunotherapy.
- CompanyArtera
Shares Patient-level multimodal foundation models for treatment selection, Pathology & radiology foundation models, AI in oncology roadmap: pattern readers → foundation models → agents in the workflow, AI that is built but not validated or deployed.
- IdeaA registry of external validation datasets for cancer AI models, with mandatory reporting
Shares Patient-level multimodal foundation models for treatment selection, Pathology & radiology foundation models, AI in oncology roadmap: pattern readers → foundation models → agents in the workflow, AI that is built but not validated or deployed.
fronts
technologies
drugs
ApprovedTissue NGS companion diagnostic test (648 genes, tumour-normal)
Tempus xT CDx · xT CDx
companies
trials
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 ExpressionA Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
roadmaps
ideas
A global federated real-world evidence network at regulatory gradeA pre-competitive consortium to train a shared multimodal cancer foundation modelA single calibrated tumour mutational burden across all sequencing panelsEmulate combination trials from real-world data to triage which ones to runEvery tumour genomic report machine-readable and deposited nationallyEvery tumour sequencing report lists open, nearby, matched trials pulled liveLabel every targetable mutation as truncal or branch on the reportPatient-level multimodal foundation models for treatment selectionTrial matching inside the electronic record at the moment a treatment is chosenValidate real-world progression against central imaging reviewWatch routine care for drug combinations that quietly make cancer treatment worse
bottlenecks
Software in use
The software of oncology →Commercial and regulated products that this organisation sells. Each card says what is behind it: a regulator's database, the literature, a public body's list, or only the company's own words. Listing is not endorsement, and a clearance is a regulatory fact, not a clinical one.
A sequencing panel and the interpretation platform Tempus reports it through, sold alongside its real-world data and trial-matching products.